Status:
COMPLETED
Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Conditions:
Ataxia Telangiectasia
Eligibility:
All Genders
2-40 years
Phase:
NA
Brief Summary
Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. The und...
Detailed Description
Ataxia telangiectasia (A-T) is a devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. For clinicia...
Eligibility Criteria
Inclusion
- Aim group: clinically and/or genetically diagnosed Ataxia telangiectasia; Control group: neurologic non-inflammatory disease with an indication for diagnostic or therapeutic lumbar puncture
- age between 2 and 40 years
- written informed consent
Exclusion
- fever or clinical signs of an infection
- leucocyte count \>12´000/µl and C reactive protein (CrP) \>2mg/dl
- chronic diseases with need of immunomodulatory therapies (bronchial asthma, rheumatoid arthritis)
- medication with statins
- other diseases with influence in the immunosystem (i.e. diabetes mellitus, malignoma, renal failure requiring dialysis)
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2017
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT02285348
Start Date
April 1 2013
End Date
July 31 2017
Last Update
August 31 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johann Wolfgang Goethe University Hospitals
Frankfurt am Main, Hesse, Germany, 60590